Optimark will undergo a voluntarily label change to notify users of the risks associated with the product. According to MSN's Market Report, Covidien announced that it will contraindicate the Optimark gadovesetamide injection. 

The injection is used as a gadolinium-based contrast agent for magnetic resonance imaging procedures. While some label changes are voluntary, gadolinium-based contrast agents have been associated with mandatory label changes in the past to inform patients about the risks. 

If you or anyone you know has suffered negative side effects as a result of being injected with a gadolinium-based contrast agent, contact the NSF and NFD lawyers of Williams Kherkher at 800-761-3187.